Alector, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALEC Nasdaq 2836 www.alector.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alector, Inc.

Global Market Stocks With Estimated Value Opportunities In February 2026 - Feb 6th, 2026 2:38 am
How The Narrative Around Alector (ALEC) Is Shifting After Index Removal And New Targets - Feb 3rd, 2026 3:10 pm
Looking At The Narrative For Alector (ALEC) After Latozinemab Setback And Cost Cuts - Jan 19th, 2026 5:11 pm
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer - Dec 12th, 2025 2:05 pm
How the Narrative Surrounding Alector Has Changed After the Latozinemab Trial Failure - Dec 5th, 2025 2:08 pm
Alector to Participate in the Bank of America CNS Therapeutics Conference - Dec 1st, 2025 2:05 pm
How Analysts See Alector’s Story Shifting After the Latest Clinical Setback - Nov 21st, 2025 1:05 pm
Alector Stock Plummets 63% in a Month: Here's What You Need to Know - Nov 18th, 2025 8:33 am
How the Narrative Around Alector Is Evolving After the Latest Clinical Setback - Nov 7th, 2025 12:13 pm
Alector (ALEC) Reports Q3 Loss, Beats Revenue Estimates - Nov 6th, 2025 4:25 pm
Alector: Q3 Earnings Snapshot - Nov 6th, 2025 3:29 pm
Alector Reports Third Quarter 2025 Financial Results and Provides Business Update - Nov 6th, 2025 2:05 pm
Alector Announces Topline Results from Phase 3 INFRONT-3 Clinical Trial Evaluating Latozinemab - Oct 31st, 2025 3:42 am
Analysts Estimate Certara, Inc. (CERT) to Report a Decline in Earnings: What to Look Out for - Oct 30th, 2025 8:00 am
Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - Oct 29th, 2025 8:00 am
Alector (ALEC): Assessing Valuation After Phase 3 Trial Failure and Major Business Overhaul - Oct 25th, 2025 5:08 pm
Why The Narrative Around Alector Is Shifting After Recent Setbacks and Analyst Downgrades - Oct 23rd, 2025 2:09 am
Alector dementia drug, partnered with GSK, fails in key study - Oct 22nd, 2025 5:22 am
Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update - Oct 21st, 2025 2:05 pm
3 Promising Penny Stocks With Market Caps Under $400M - Oct 8th, 2025 6:05 am